Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.12.2009 | Epidemiology

Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk

verfasst von: Daniele Campa, James McKay, Olga Sinilnikova, Anika Hüsing, Ulla Vogel, Rikke Dalgaard Hansen, Kim Overvad, Petra Mariann Witt, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Veronique Chajes, Sabine Rohrmann, Jenny Chang-Claude, Heiner Boeing, Eva Fisher, Antonia Trichopoulou, Dimitrios Trichopoulos, Domenico Palli, Anna Villarini, Carlotta Sacerdote, Amalia Mattiello, Rosario Tumino, Petra H. M. Peeters, Carla H. van Gils, H. Bas Bueno-de-Mesquita, Eiliv Lund, María Dolores Chirlaque, Núria Sala, Laudina Rodriguez Suarez, Aurelio Barricarte, Miren Dorronsoro, Maria-José Sánchez, Per Lenner, Göran Hallmans, Kostas Tsilidis, Sheila Bingham, Kay-Tee Khaw, Valentina Gallo, Teresa Norat, Elio Riboli, Sabina Rinaldi, Gilbert Lenoir, Sean V. Tavtigian, Federico Canzian, Rudolf Kaaks

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Fatty acid synthase (FAS) is the major enzyme of lipogenesis. It catalyzes the NADPH-dependent condensation of acetyl-CoA and malonyl-CoA to produce palmitic acid. Transcription of the FAS gene is controlled synergistically by the transcription factors ChREBP (carbohydrate response element-binding protein), which is induced by glucose, and SREBP-1 (sterol response element-binding protein-1), which is stimulated by insulin through the PI3K/Akt signal transduction pathway. We investigated whether the genetic variability of the genes encoding for ChREBP, SREBP and FAS (respectively, MLXIPL, SREBF1 and FASN) is related to breast cancer risk and body-mass index (BMI) by studying 1,294 breast cancer cases and 2,452 controls from the European Prospective Investigation on Cancer (EPIC). We resequenced the FAS gene and combined information of SNPs found by resequencing and SNPs from public databases. Using a tagging approach and selecting 20 SNPs, we covered all the common genetic variation of these genes. In this study we were not able to find any statistically significant association between the SNPs in the FAS, ChREBP and SREPB-1 genes and an increased risk of breast cancer overall and by subgroups of age, menopausal status, hormone replacement therapy (HRT) use or BMI. On the other hand, we found that two SNPs in FASN were associated with BMI.
Literatur
5.
Zurück zum Zitat Kaaks R, Lukanova A (2002) Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann N Y Acad Sci 963:268–281PubMedCrossRef Kaaks R, Lukanova A (2002) Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann N Y Acad Sci 963:268–281PubMedCrossRef
6.
Zurück zum Zitat Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed Muti P, Quattrin T, Grant BJ et al (2002) Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 11:1361–1368PubMed
9.
Zurück zum Zitat Krajcik RA, Borofsky ND, Massardo S et al (2002) Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566–1573PubMed Krajcik RA, Borofsky ND, Massardo S et al (2002) Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer. Cancer Epidemiol Biomarkers Prev 11:1566–1573PubMed
12.
Zurück zum Zitat Key T, Appleby P, Barnes I et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616PubMed Key T, Appleby P, Barnes I et al (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–616PubMed
13.
16.
17.
Zurück zum Zitat Andreolas C, da Silva Xavier G, Diraison F et al (2002) Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51:2536–2545. doi:10.2337/diabetes.51.8.2536 CrossRefPubMed Andreolas C, da Silva Xavier G, Diraison F et al (2002) Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells. Diabetes 51:2536–2545. doi:10.​2337/​diabetes.​51.​8.​2536 CrossRefPubMed
18.
Zurück zum Zitat Diraison F, Parton L, Ferre P et al (2004) Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem J 378:769–778. doi:10.1042/BJ20031277 CrossRefPubMed Diraison F, Parton L, Ferre P et al (2004) Over-expression of sterol-regulatory-element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR). Biochem J 378:769–778. doi:10.​1042/​BJ20031277 CrossRefPubMed
19.
Zurück zum Zitat Rufo C, Teran-Garcia M, Nakamura MT et al (2001) Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription. J Biol Chem 276:21969–21975. doi:10.1074/jbc.M100461200 CrossRefPubMed Rufo C, Teran-Garcia M, Nakamura MT et al (2001) Involvement of a unique carbohydrate-responsive factor in the glucose regulation of rat liver fatty-acid synthase gene transcription. J Biol Chem 276:21969–21975. doi:10.​1074/​jbc.​M100461200 CrossRefPubMed
21.
Zurück zum Zitat Alo PL, Visca P, Trombetta G et al (1999) Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85:35–40. doi:10.1159/000015275 PubMed Alo PL, Visca P, Trombetta G et al (1999) Fatty acid synthase (FAS) predictive strength in poorly differentiated early breast carcinomas. Tumori 85:35–40. doi:10.​1159/​000015275 PubMed
22.
Zurück zum Zitat Milgraum LZ, Witters LA, Pasternack GR et al (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115–2120PubMed Milgraum LZ, Witters LA, Pasternack GR et al (1997) Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 3:2115–2120PubMed
23.
Zurück zum Zitat Pizer ES, Wood FD, Heine HS et al (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189–1193PubMed Pizer ES, Wood FD, Heine HS et al (1996) Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res 56:1189–1193PubMed
24.
Zurück zum Zitat Rashid A, Pizer ES, Moga M et al (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150:201–208PubMed Rashid A, Pizer ES, Moga M et al (1997) Elevated expression of fatty acid synthase and fatty acid synthetic activity in colorectal neoplasia. Am J Pathol 150:201–208PubMed
28.
Zurück zum Zitat Swinnen JV, Roskams T, Joniau S et al (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19–22. doi:10.1002/ijc.10127 CrossRefPubMed Swinnen JV, Roskams T, Joniau S et al (2002) Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 98:19–22. doi:10.​1002/​ijc.​10127 CrossRefPubMed
31.
Zurück zum Zitat Pizer ES, Jackisch C, Wood FD et al (1996) Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745–2747PubMed Pizer ES, Jackisch C, Wood FD et al (1996) Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 56:2745–2747PubMed
32.
Zurück zum Zitat Pizer ES, Thupari J, Han WF et al (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213–218PubMed Pizer ES, Thupari J, Han WF et al (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60:213–218PubMed
33.
Zurück zum Zitat Thupari JN, Pinn ML, Kuhajda FP (2001) Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285:217–223. doi:10.1006/bbrc.2001.5146 CrossRefPubMed Thupari JN, Pinn ML, Kuhajda FP (2001) Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 285:217–223. doi:10.​1006/​bbrc.​2001.​5146 CrossRefPubMed
36.
Zurück zum Zitat Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124. doi:10.1079/PHN2002394 CrossRefPubMed Riboli E, Hunt KJ, Slimani N et al (2002) European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 5:1113–1124. doi:10.​1079/​PHN2002394 CrossRefPubMed
37.
38.
Zurück zum Zitat Carlson CS, Eberle MA, Rieder MJ et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120. doi:10.1086/381000 CrossRefPubMed Carlson CS, Eberle MA, Rieder MJ et al (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120. doi:10.​1086/​381000 CrossRefPubMed
40.
Zurück zum Zitat Medes G, Thomas A, Weinhouse S (1953) Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 13:27–29PubMed Medes G, Thomas A, Weinhouse S (1953) Metabolism of neoplastic tissue. IV. A study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res 13:27–29PubMed
42.
Zurück zum Zitat Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:765–769. doi:10.1086/383251 CrossRefPubMed Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 74:765–769. doi:10.​1086/​383251 CrossRefPubMed
Metadaten
Titel
Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk
verfasst von
Daniele Campa
James McKay
Olga Sinilnikova
Anika Hüsing
Ulla Vogel
Rikke Dalgaard Hansen
Kim Overvad
Petra Mariann Witt
Françoise Clavel-Chapelon
Marie-Christine Boutron-Ruault
Veronique Chajes
Sabine Rohrmann
Jenny Chang-Claude
Heiner Boeing
Eva Fisher
Antonia Trichopoulou
Dimitrios Trichopoulos
Domenico Palli
Anna Villarini
Carlotta Sacerdote
Amalia Mattiello
Rosario Tumino
Petra H. M. Peeters
Carla H. van Gils
H. Bas Bueno-de-Mesquita
Eiliv Lund
María Dolores Chirlaque
Núria Sala
Laudina Rodriguez Suarez
Aurelio Barricarte
Miren Dorronsoro
Maria-José Sánchez
Per Lenner
Göran Hallmans
Kostas Tsilidis
Sheila Bingham
Kay-Tee Khaw
Valentina Gallo
Teresa Norat
Elio Riboli
Sabina Rinaldi
Gilbert Lenoir
Sean V. Tavtigian
Federico Canzian
Rudolf Kaaks
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0347-8

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.